Polypid opened higher at $6.74, compared with its previous close of $6.60. In the last trading session, the stock traded between $6.33 and $6.97. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Polypid is now worth
$ 2.76
Resulting in a loss of
$ 97.24 (97.24%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.20 (-3.02%)
Day High
$6.97
Day Low
$6.33
Day Open
$6.74
Prev Close
$6.60
Volume
1,79,097
1W Return
10.57%
1M Return
27.10%
3M Return
35.18%
6M Return
47.49%
1Y Return
70.24%
Market Cap ($ Mn)
130
PE Ratio
-
PB Ratio
19.11
PEG Ratio
-
ROE
-312.99%
ROCE
-224.42%
EPS (TTM)
$-0.41
1 Week
10.57%
1 Month
27.10%
3 Months
35.18%
6 Months
47.49%
9 Months
38.55%
PolyPid Q3 loss narrows to $5.8m as PDUFA date set for Nov 28
Net loss narrowed to $5.8 million in Q3FY26 from $7.5 million in Q3FY25. PDUFA goal date for D-PLEX100 is November 28, 2026, with US launch planned for early 2027. R&D expenses rose 22.6% to $6.5 million due to NDA-related activities. Cash reserves stand at $15.5 million, bolstered by a recent $15 million milestone payment.
YesterdayPolyPid to host virtual investor day on Oct 28 to outline 2030 strategy
Virtual Investor Day scheduled for October 28, 2026. Management to outline 'PolyPid 2030' long-term strategy. Update provided on D-PLEX100 NDA under FDA Priority Review. Introduction of PD01B for diabetic foot infections using Kynatrix technology. Key Opinion Leader Warren S. Joseph to discuss clinical burdens.
28 days agoPolyPid Q2 losses narrow 55%, FDA accepts D-PLEX100 NDA
PolyPid Ltd (NASDAQ: PYPD) reported Q2 2026 EPS of $(0.35), beating estimates by 7.89% as net losses narrowed 55% YoY to $7.8 million. Key drivers included lower G&A expenses and an FDA-accepted NDA for D-PLEX100 with Priority Review. The company secured $30 million upfront from partner Azurity, strengthening its balance sheet for a potential early 2027 launch.
3mo agoPolyPid secures FDA acceptance, triggers $15M Azurity milestone
PolyPid Ltd. announced FDA acceptance of its NDA for D-PLEX100 with Priority Review, accelerating the PDUFA action date to November 28, 2026. This event triggers a $15 million milestone payment from partner Azurity Pharmaceuticals, bringing total near-term payments to $30 million.
3mo agoHC Wainwright reiterates Buy on PolyPid, maintains $13 target
HC Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on PolyPid, maintaining a price target of $13. The firm's endorsement reflects continued confidence in the stock's valuation.
3mo agoPolyPid partners with Azurity for D-PLEX100 commercialization
PolyPid Ltd. has partnered with Azurity Pharmaceuticals to commercialize D-PLEX100 in the U.S. and Canada for preventing surgical site infections. The deal includes $15 million upfront, $15 million upon FDA NDA acceptance expected in August 2026, and up to $300 million in additional milestones. PolyPid retains rights outside North America and will manufacture the product, with a U.S. launch targeted for Q1 2027.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Polypid is now worth
$ 2.76
Resulting in a loss of
$ 97.24 (97.24%)
Note: Past profits do not guarantee future returns.
